Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy
Author:
Affiliation:
1. Eli Lilly and Company, Indianapolis, IN, USA;
2. Evidera, Bethesda, MD, USA;
3. Eli Lilly Italia S.p.A, Sesto Fiorentino, Italy;
4. Formerly with Eli Lilly Italia S.p.A, Sesto Fiorentino, Italy;
5. Eli Lilly Finland, Helsinki, Finland
Funder
Eli Lilly and Company
Publisher
Informa UK Limited
Subject
Health Policy
Link
https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1609482
Reference48 articles.
1. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2. Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
3. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
4. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Health state utilities associated with weight loss: preferences of people with type 2 diabetes and obesity in Japan;Journal of Medical Economics;2024-03-11
2. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States;Journal of Managed Care & Specialty Pharmacy;2024-02-03
3. Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States;Diabetes Therapy;2023-11-18
4. Disutilities Associated with Intravenous Iron Infusions: Results from a Time Trade-off Survey and Diminishing Marginal Utility Model for Treatment Attributes in China;Patient Related Outcome Measures;2023-09
5. Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment;PharmacoEconomics;2023-01-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3